Skip to content

Enter Ticker for All in One Deep Dive Analysis • Enter Ticker for All in One Deep Dive Analysis • Enter Ticker for All in One Deep Dive Analysis • Enter Ticker for All in One Deep Dive Analysis •

Stock Options Analysis Options Chain Advanced Charts Stock Options Education Economic Calendar Earnings Calendar Insider Trades IPOs Calendar Watchlist Portfolio Tracker Stock Screener Options Calculators Market Insights New IPOs Senate & House Trades Heatmaps Technical Chart Series Stock Splits Calendar Top Performers Earnings Move Analyzer Stock Options Analysis Options Chain Advanced Charts Stock Options Education Economic Calendar Earnings Calendar Insider Trades IPOs Calendar Watchlist Portfolio Tracker Stock Screener Options Calculators Market Insights New IPOs Senate & House Trades Heatmaps Technical Chart Series Stock Splits Calendar Top Performers Earnings Move Analyzer

Home
Expert Articles
Calendars
Financial Tools
Option Tools
- Options Chain
- Options Calculators
About

Stock Options Analysis Options Chain Advanced Charts Stock Options Education Economic Calendar Earnings Calendar IPOs Calendar Stock Splits Calendar Watchlist Portfolio Tracker Stock Screener Options Calculators Market Insights New IPOs Senate & House Trades Heatmaps Technical Chart Series Insider Trades Top Performers Earnings Move Analyzer Stock Options Analysis Options Chain Advanced Charts Stock Options Education Economic Calendar Earnings Calendar IPOs Calendar Stock Splits Calendar Watchlist Portfolio Tracker Stock Screener Options Calculators Market Insights New IPOs Senate & House Trades Heatmaps Technical Chart Series Insider Trades Top Performers Earnings Move Analyzer

Enter Ticker for All in One Deep Dive Analysis • Enter Ticker for All in One Deep Dive Analysis • Enter Ticker for All in One Deep Dive Analysis • Enter Ticker for All in One Deep Dive Analysis •

Home
Expert Articles
Calendars
Financial Tools
Option Tools
- Options Chain
- Options Calculators
About

Ticker

No recent analyst price targets found for HNSA.ST.

Latest News for HNSA.ST

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia PR Newswire

GuruFocus • Aug 18, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for HNSA.ST.

Senate Trading

No Senate trades found for HNSA.ST.

U.S. House Trading

No House trades found for HNSA.ST.

Enter Ticker Symbol: Strikes:

Options Chain Settings

Changes apply instantly as you toggle. Tap Done when finished.

Bid/Ask/Mark (first):

Bid Ask Mark

Core Metrics:

Volume OI IV % Delta Theta Vega

More Greeks (optional):

Gamma Rho Phi

Valuation:

Intrinsic Extrinsic Theoretical

Price & Momentum:

Last Change ($) % Change Avg Vol High & Low

IV Variants:

Bid IV Mid IV Ask IV SMV Vol

IV Units:

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Capital Risk Disclosure & Investment Advisory Disclaimer

All content provided on this platform — including but not limited to stock picks, technical analysis, option strategies, financial data, opinion articles, and educational materials — is for informational and educational purposes only.

The analyses are powered by intelligent AI-based stock pick analysis with editor review, leveraging real-time and historical data where available. While our system strives for accuracy and actionable insight, no guarantees are made regarding accuracy, completeness, or future performance.

None of the information presented constitutes investment, legal, or tax advice. The content is not a solicitation or recommendation to buy or sell any securities. Always conduct your own due diligence and consider consulting with a licensed financial advisor or registered investment professional before making any investment decisions.

Options and other forms of leveraged investing involve significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Do not allocate more than 2 percent of your total portfolio to any single trade, position, or strategy.

All opinions expressed are those of the authors and contributors and are subject to change without notice.

Our stock options analysis is not for day trading but for medium to long term options trading.

Use of this platform implies agreement with this disclaimer.

By Founder Andrew Citra & Co-Founder Victorius Djono

Email: andrewc@vixtradinghub.com

Email: victoriousd@vixtradinghub.com

Home
Expert Articles
Calendars
Financial Tools
Option Tools
About

Copyright © 2026 vixtradinghub.com

Scroll to Top